Article Details

Hepion Pharmaceuticals (NASDAQ:HEPA) Downgraded to “Hold” at Zacks Investment Research

Retrieved on: 2022-05-27 14:55:12

Tags for this article:

Click the tags to see associated articles and topics

Hepion Pharmaceuticals (NASDAQ:HEPA) Downgraded to “Hold” at Zacks Investment Research. View article details on hiswai:

Excerpt

Renaissance Technologies LLC now owns 126,600 shares of the company's stock valued at $163,000 after acquiring an additional 76,300 shares during the ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up